Strategies for Safe and Efficacious Use of New and Emerging Therapies in HCV (Enduring)

Title:

Strategies for Safe and Efficacious Use of New and Emerging Therapies in HCV (Enduring)

Topic: Gastroenterology
Relevant Terms: HCV; drug-drug interactions; interferon-free regimens; HIV/HCV coinfection
Primary Audience: Gastroenterologists, hepatologists, nurse practitioners, physician assistants, and other health care professionals involved in the treatment of patients with HCV.
Launch Date: 03-Nov-15
Credits: AMA PRA Category 1 Credit
Expiration Date: 31-Jul-17
Curriculum Name: Strategies for Safe and Efficacious Use of New and Emerging Therapies in HCV

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Discuss the importance of HCV treatment and achievement of sustained viral response for improvement of hepatic and extrahepatic manifestations in mild as well as severe disease.
  2. Apply the clinical evidence to optimize treatment duration, monitoring strategies, and drug-drug interactions for newly approved and emerging interferon-free regimens.
  3. Appraise the clinical evidence to determine how to optimize the use of newly approved and emerging interferon-free regimens in special populations of patients including those with decompensated cirrhosis, HIV/HCV coinfection, transplant/post-transplant of liver, renal impairment, and HCV genotype 3.

    Faculty

    Ira Jacobson, MD
    Chairman, Department of Medicine
    Mount Sinai Beth Israel Medical Center
    Vice Chair of Medicine
    Mount Sinai Health Care System
    Senior Faculty, Icahn School of Medicine at Mount Sinai
    New York, NY
    Nancy Reau, MD, FAASLD, AGAF
    Associate Professor of Medicine
    Section Chief, Hepatology
    Associate Director of Solid Organ Transplantation
    Rush University Medical Center
    Chicago, IL
    Provided by Vindico Medical Education  

    Release Date: November 3, 2015
    Expiration Date: July 31, 2017
     
    Physician Continuing Medical Education 
     
    Accreditation Statement
    Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
     
    Credit Designation
    Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     
    Type of Activity 
    Knowledge and Performance

    Target Audience 
    The intended audience for this activity is gastroenterologists, hepatologists, nurse practitioners, physician assistants, and other health care professionals involved in the treatment of patients with HCV.

    Educational Support 
    This activity is supported by an educational grant from Gilead Sciences Medical Affairs.

    Disclosure of Conflicts of Interest
    In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
     
    Faculty 
    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

    Andrew J. Muir, MD, MHS has received Consulting Fees: AbbVie, Achillion, Bristol-Myers Squibb, Gilead, Janssen, Merck, Theravance.
    Contracted Research: AbbVie, Achillion, Bristol-Myers Squibb, Gilead, Janssen, Merck, Roche, Theravance.

    Mark Sulkowski, MD has received Consulting Fees: AbbVie, Achillion, Gilead, Janssen, Merck.
    Contracted Research (paid directly to institution): AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck.

    Ira Jacobson, MD has received Consulting Fees: AbbVie, Achillion, Bristol-Myers Squibb, Enanta, Gilead, Janssen, Merck
    Speakers Bureau: AbbVie, Bristol-Myers Squibb, Gilead, Janssen
    Contracted Research: AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck, Tobira

    Nancy Reau, MD, FAASLD, AGAF has received Consulting Fees: AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Salix.
    Contracted Research: AbbVie, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, Merck.
     
    External Reviewers
    Joseph K. Lim, MD has received Consulting Fees: Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, Merck.
    Contracted Research: Abbott, Bristol-Myers Squibb, Gilead, Hologic, Janssen.
     
    Ronald A. Codario, MD, FACP, FNLA, CCMEP has no relevant financial relationship to disclose.
     
    Planners 
    Vindico Medical Education Staff: No relevant financial relationships to disclose.
     
    Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance. 
     
    Disclosure of Unlabeled Use
    The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
     
    Media 
    Internet 
     
    Disclaimer
    The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the U.S. Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

    Method of Participation and Request for Credit 
    To participate in this CME activity, you must complete the activity in its entirety and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
     
     
    COURSE VIEWING REQUIREMENTS
    Supported Browsers:
    Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1   
    ** Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 6.0+ for Mac OSX 10.7 and above

    For video playback, install the latest version of Flash or Quicktime.
     
    ** If you are experiencing video playback issues with Google Chrome, please refer to a support article by clicking here
     
    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 7.0 or above